The ODPRN has conducted multiple studies that have both informed and evaluated the impact of drug policies in Ontario, and more broadly across Canada. This research includes a wide breadth of work ranging from large drug class reviews to specific rapid response projects resulting from decision makers’ pressing initiatives.
To reduce the risk of prescription opioid-related overdoses and diversion, on January 31, 2017 the Ontario Public Drug Programs delisted (removed) all high-strength opioids from their formulary, making them no longer eligible for reimbursement. An exception was made for palliative patients.
This study evaluates whether the delisting policy impacted access to prescription opioids and daily opioid doses among public drug beneficiaries who were receiving these high-strength opioids.